Mariano Provencio-Pulla

Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.

Mariano Provencio-Pulla, Ernest Nadal-Alforja, Manuel Cobo et al. · Journal of Clinical Oncology · 2018 · 68 citations

Surgical Oncology, Medicine, High Response Rate +12

Differential crizotinib response duration among ALK fusion variants in ALK-positive non–small-cell lung cancer

Alberto Ruano‐Raviña, Mariano Provencio-Pulla · Translational Cancer Research · 2017 · 65 citations · Full text

Oncology, Medicine, Cancer Genomics +8

Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.

Mariano Provencio-Pulla, Ernest Nadal, J.L. González-Larriba et al. · Journal of Clinical Oncology · 2022 · 61 citations

Surgical Oncology, Oncology, Pcr Rate +13

Differential crizotinib response duration among ALK fusion variants in ALK-positive non–small-cell lung cancer

Alberto Ruano‐Raviña, Mariano Provencio-Pulla · Translational Cancer Research · 2017 · 37 citations

Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816.

Mariano Provencio-Pulla, Jonathan Spicer, Janis M. Taube et al. · Journal of Clinical Oncology · 2022 · 19 citations

Surgical Oncology, Primary Endpoints, Medicine +12